Share-based Payment Arrangement, Expense of UroGen Pharma Ltd. from 31 Dec 2015 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
UroGen Pharma Ltd. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2015 to 30 Sep 2025.
  • UroGen Pharma Ltd. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $3,027,000, a 13% decline year-over-year.
  • UroGen Pharma Ltd. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $12,132,000, a 2.3% decline year-over-year.
  • UroGen Pharma Ltd. annual Share-based Payment Arrangement, Expense for 2024 was $13,108,000, a 40% increase from 2023.
  • UroGen Pharma Ltd. annual Share-based Payment Arrangement, Expense for 2023 was $9,344,000, a 12% decline from 2022.
  • UroGen Pharma Ltd. annual Share-based Payment Arrangement, Expense for 2022 was $10,580,000, a 54% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

UroGen Pharma Ltd. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $12,132,000 $3,027,000 -$462,000 -13% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $12,594,000 $2,733,000 -$827,000 -23% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $13,421,000 $3,069,000 +$313,000 +11% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $13,108,000 $3,303,000 +$691,000 +26% 01 Oct 2024 31 Dec 2024 10-K 10 Mar 2025 2024 FY
Q3 2024 $12,417,000 $3,489,000 +$1,265,000 +57% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $11,152,000 $3,560,000 +$1,338,000 +60% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $9,814,000 $2,756,000 +$470,000 +21% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $9,344,000 $2,612,000 +$244,000 +10% 01 Oct 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
Q3 2023 $9,100,000 $2,224,000 -$216,000 -8.9% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $9,316,000 $2,222,000 -$601,000 -21% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $9,917,000 $2,286,000 -$663,000 -22% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q4 2022 $10,580,000 $2,368,000 -$2,989,000 -56% 01 Oct 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 $13,569,000 $2,440,000 -$3,075,000 -56% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $16,644,000 $2,823,000 -$3,223,000 -53% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $19,867,000 $2,949,000 -$3,246,000 -52% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $23,113,000 $5,357,000 -$1,169,000 -18% 01 Oct 2021 31 Dec 2021 10-K 24 Mar 2023 2022 FY
Q3 2021 $24,282,000 $5,515,000 -$1,248,000 -18% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $25,530,000 $6,046,000 -$1,073,000 -15% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $26,603,000 $6,195,000 -$1,422,000 -19% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $28,025,000 $6,526,000 -$1,539,000 -19% 01 Oct 2020 31 Dec 2020 10-K 21 Mar 2022 2021 FY
Q3 2020 $29,564,000 $6,763,000 -$480,000 -6.6% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $30,044,000 $7,119,000 -$93,000 -1.3% 01 Apr 2020 30 Jun 2020 10-Q 04 Aug 2021 2021 Q2
Q1 2020 $30,137,000 $7,617,000 +$170,000 +2.3% 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q4 2019 $29,967,000 $8,065,000 -$812,000 -9.1% 01 Oct 2019 31 Dec 2019 10-K 18 Mar 2021 2020 FY
Q3 2019 $30,779,000 $7,243,000 -$2,272,000 -24% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $33,051,000 $7,212,000 -$497,000 -6.4% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $33,548,000 $7,447,000 +$2,906,000 +64% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $30,642,000 $8,877,000 +$6,608,000 +291% 01 Oct 2018 31 Dec 2018 10-K 02 Mar 2020 2019 FY
Q3 2018 $24,034,000 $9,515,000 +$7,357,000 +341% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $16,677,000 $7,709,000 +$6,133,000 +389% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019 2019 Q2
Q1 2018 $10,544,000 $4,541,000 +$4,244,000 +1429% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $6,300,000 $2,269,000 01 Oct 2017 31 Dec 2017 10-K 02 Mar 2020 2019 FY
Q3 2017 $2,158,000 01 Jul 2017 30 Sep 2017 6-K 13 Nov 2018 2018 Q3
Q2 2017 $1,576,000 01 Apr 2017 30 Jun 2017 6-K 14 Aug 2018 2018 Q2
Q1 2017 $297,000 01 Jan 2017 31 Mar 2017 6-K 15 May 2018 2018 Q1

UroGen Pharma Ltd. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $13,108,000 +$3,764,000 +40% 01 Jan 2024 31 Dec 2024 10-K 10 Mar 2025 2024 FY
2023 $9,344,000 -$1,236,000 -12% 01 Jan 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
2022 $10,580,000 -$12,533,000 -54% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
2021 $23,113,000 -$4,912,000 -18% 01 Jan 2021 31 Dec 2021 10-K 24 Mar 2023 2022 FY
2020 $28,025,000 -$1,942,000 -6.5% 01 Jan 2020 31 Dec 2020 10-K 21 Mar 2022 2021 FY
2019 $29,967,000 -$675,000 -2.2% 01 Jan 2019 31 Dec 2019 10-K 18 Mar 2021 2020 FY
2018 $30,642,000 +$24,342,000 +386% 01 Jan 2018 31 Dec 2018 10-K 02 Mar 2020 2019 FY
2017 $6,300,000 +$4,333,000 +220% 01 Jan 2017 31 Dec 2017 10-K 02 Mar 2020 2019 FY
2016 $1,967,000 +$1,518,000 +338% 01 Jan 2016 31 Dec 2016 10-K 28 Feb 2019 2018 FY
2015 $449,000 01 Jan 2015 31 Dec 2015 20-F 15 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.